Generic drug bottle



DHHS recommendation not yet established
Entry Inhibitor

Standard Dose

Investigational drug at press time. In clinical trials, the investigational dose taken forward for further study was 600 mg twice daily without regard to food. Doses were taken after eating. Must be taken in combination with another antiretroviral(s).

Recommended for heavily treatment-experienced patients with history of three-class antiretroviral resistance in addition to an optimized background regimen of other active antiretroviral drugs. Not studied in treatment-naïve patients. No data in pregnant women or pediatric patients under age 18 years.

Take missed dose as soon as possible, unless it is closer in time to your next dose. Do not double up on your next dose.

See package insert when available for more complete information on potential side effects and interactions.

Investigational drug at press time.


ViiV Healthcare
(877) 844-8872


Not yet established.

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments